Methods and compositions related to bacterial delivery of RNA

Engineered bacteria deliver and translate circRNA within mammalian cells, addressing the inefficiencies and safety concerns of current nanoparticle-based methods by providing a targeted and effective circRNA delivery system.

WO2026241525A1PCT designated stage Publication Date: 2026-11-19BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028196
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current methods for delivering circular RNA (circRNA) therapeutics require synthesis with lipid nanoparticles and injection, leading to random interactions with mammalian cells, posing safety and efficacy challenges.

Method used

Engineered bacteria capable of invading eukaryotic cells, carrying a non-chromosomal genetic element that expresses circRNA and facilitates its translation, providing a safe and effective delivery system.

Benefits of technology

The engineered bacteria efficiently deliver and translate circRNA within mammalian cells, offering a safer and more targeted therapeutic approach compared to existing nanoparticle-based methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000013_0001
    Figure IMGF000013_0001
  • Figure IMGF000020_0001
    Figure IMGF000020_0001
  • Figure 00000026_0000
    Figure 00000026_0000
Patent Text Reader

Abstract

Disclosed are engineered bacteria capable of invading a eukaryotic cell, wherein said bacteria comprises a non-chromosomal genetic element, wherein said genetic element comprises a template for expression of circular mRNA (circRNA), and further wherein the genetic element comprises one or more components which facilitate circRNA translation by a eukaryotic ribosome. Also disclosed are methods of using the engineered bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No. 10046-681W01

[0002] METHODS AND COMPOSITIONS RELATED TO

[0003] BACTERIAL DELIVERY OF RNA

[0004] CROSS-REFERENCE TO RELATED APPLICATIONS

[0005] This application claims benefit of U. S. Provisional Application No. 63 / 805,604, filed May 14, 2025, incorporated herein by reference in its entirety.

[0006] BACKGROUND

[0007] Previous research has shown that attenuated, invasive bacteria can be used to delivery DNA plasmids into mammalian cells (Darji 1997). But the efficiency of DNA plasmid delivery is poor as it needs to migrate to the nucleus for expression.

[0008] Today, circular RNA (circRNA) is taking off for gene delivery due to its stability and ease of synthesis over linear RNA (Chen 2023). The exploration of circRNAs as therapeutics is rapidly gaining momentum, driven by their inherent stability, resistance to exonucleases, and capacity for functional modulation of gene expression. Unlike linear RNAs, circRNAs can persist in cells for extended periods, making them attractive candidates for long-lasting therapeutic interventions (Id 2015). Synthetic circRNAs have been engineered to act as miRNA sponges or decoys, sequestering oncogenic miRNAs with high specificity (Liu 2022). Additionally, translationally active circRNAs have been designed with internal ribosome entry sites (IRES) or m6A modifications to produce functional peptides, expanding their potential utility beyond noncoding functions (Yang 2017).

[0009] Several proof-of-concept studies have demonstrated the efficacy of circRNA-based interventions in preclinical disease models. For example, engineered circRNA constructs targeting miR-21 have successfully suppressed tumor growth in glioblastoma models by restoring PTEN expression (Zhang 2021). In cardiovascular disease, delivery of synthetic circRNAs encoding protective peptides has shown benefit in reducing myocardial infarct size and improving cardiac function post-injury (Huang 2020). These successes are supported by¬ advances in delivery technologies, including lipid nanoparticles and exosome-based systems, which facilitate targeted and efficient delivery of circRNA therapeutics to specific tissues (Zhou 2022).

[0010] Despite promising progress, challenges remain before circRNAs can be translated into clinical therapies. For example, all current uses require RNA to be synthesized and mixedAttorney Docket No. 10046-681W01

[0011] with lipid nanoparticles for delivery. This form of delivery requires injection, and the nanoparticles have displayed random interactions with mammalian cells. What is needed in the art are safe and effective methods and compositions for delivery of circRNA to subjects in need thereof.

[0012] SUMMARY

[0013] Disclosed herein is an engineered bacteria capable of invading a eukaryotic cell, wherein said bacteria comprises a non-chromosomal genetic element, wherein said genetic element comprises a template for expression of circular mRNA (circRNA), and further wherein the genetic element comprises one or more components which facilitate circRNA translation by a eukaryotic ribosome.

[0014] Also disclosed is a method of delivering a therapeutic composition to a subject in need thereof, the method comprising administering to the subject an engineered bacteria capable of invading a eukaryotic cell, wherein said bacteria comprises a non-chromosomal genetic element, wherein said genetic element comprises a template for expression of circRNA, and further wherein the genetic element comprises one or more components which facilitate circRNA translation by a eukaryotic ribosome.

[0015] DESCRIPTION OF DRAWINGS

[0016] Figure 1 is a schematic illustrating delivery of a circular RNA encoding luciferase to mammalian cells using an invasive, attenuated bacterium. The upper portion depicts the bacterium (capsule-shaped cell) carrying a plasmid encoding luciferase, which is transcribed into a linear precursor RNA and then circularized via flanking introns to yield a circular RNA encoding luciferase. The plasmid is shown as a circular construct with a green segment and a red (luciferase-encoding) segment; the precursor RNA is shown as a sinuous strand; and the circular RNA is shown as a closed red circle. The lower portion depicts a three-step cellular workflow connected by arrows. In the first petri dish, mammalian cells (spheroids) are infected with the bacterium expressing the circular RNA. The central panel shows a mammalian host cell in cross-section containing an internalized bacterium within a vacuole, with an adjacent signal representing circular RNA released upon intracellular degradation of the bacterium. In the third petri dish, a subset of the mammalian cells is shaded to indicate expression of luciferase translated from the delivered circular RNA. Collectively, this figure illustrates bacterial delivery of an intron-circularized RNA to mammalian cells, where bacterial degradation releases the circular RNA for translation by the host cell.

[0017] Attorney Docket No. 10046-681W01

[0018] Figure 2 shows circular RNA delivery with Shigella. Hela cells were treated with vaccine strain Shigella flexinera CVD1208 encoding i) an empty plasmid control or ii) a plasmid expressing circular RNA encoding Luciferase LVA or iii) Luciferase with no IRES for mammalian translation. The indicated MOI were tested. Only cells treated with Shigella flexinera CVD1208 encoding a plasmid expressing circular RNA encoding Luciferase LVA showed luciferase signal that increased from 1 to 3 days. When no IRES was present, minimal luciferase signal was observed, and signal decreased over time.

[0019] Figure 3 shows circular RNA delivery with Salmonella. Hela cells were treated with Salmonella typhimurium strain VNP20009 encoding i) an empty plasmid control or ii) a plasmid expressing circular RNA encoding Luciferase. The indicated MOI were tested. Only cells treated with VNP20009 encoding a plasmid expressing circular RNA encoding Luciferase showed luciferase signal that increased from 1 to 3 days.

[0020] Figure 4 shows delivery of luciferase circular RNA in vivo. Shigella encoding an empty vector (cont) or expressing a circular RNA (nluc) for production of luciferase from a mammalian promoter were administered intranasally to adult CD1 mice in duplicate. 3 days post inoculation, nasal cavities were extracted and evaluated for luciferase activity compared to a PBS control. The control mice (cont-1 and cont-2) showed no luciferase activity compared to a PBS control. Both mice receiving the circular RNA plasmid showed luciferase expression significantly above control mice and PBS.

[0021] Figure 5 shows the ability of Shigella vaccine strain to deliver circular RNA expressing nanoluc to the mouse lung. The lung is frequently to test bacterial interactions with mucosal surfaces. Shigella carried a plasmid expressing circular RNA encoding nanoluc or a control that expressed a similar mRNA without introns that could not circularize. Mice were inoculated with one dose. After three days lungs were evaluated for nanoluc signal. All three mice heated with circular RNA encoding nanoluc showed a strong luminescence signal while none of the control mice showed a signal. This indicates that RNA was delivered to the lung epithelium and that circularization was required for signal after three days. Significance (* p = 0.0232) was determined by a Welch’s t test.

[0022] Figure 6 shows that, using the same target RNA, the amount of circular RNA produced in bacteria can be increased by using stronger promoters. The results show using a high expression promoter produces ~3X the amount of circular RNA compared to the baseline construct. Significance (* p > 0.001) was determined by ANOVA with a Dunnett’s multiple comparisons test across circular RNA samples.

[0023] Attorney Docket No. 10046-681W01

[0024] DETAILED DESCRIPTION

[0025] General Definitions

[0026] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs.

[0027] Ranges can be expressed herein as from “about” one particular value, and / or to “about” another particular value. By “about” is meant within 10% of the value, e.g., within 9, 8, 8, 7, 6, 5, 4, 3, 2, or 1% of the value. When such a range is expressed, another aspect includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular' value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed.

[0028] The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of’ and “consisting of’ can be used in place of “comprising” and “including” to provide for more specific embodiments and are also disclosed. Throughout the description and claims of this specification the word “comprise” and other forms of the word, such as “comprising” and “comprises,” means including but not limited to, and is not intended to exclude, for example, other additives, components, integers, or steps.

[0029] As used in the specification and claims, the singular form “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. For example, the term “an agent” includes a plurality of agents, including mixtures thereof.

[0030] As used herein, the terms "may," "optionally," and "may optionally" are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur. Thus, for example, the statement that a formulation "may include an excipient" is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient.

[0031] Attorney Docket No. 10046-681W01

[0032] 'Inhibit,” "inhibiting," and "inhibition" mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.

[0033] By “reduce,” or “abrogate,” (used interchangeably) or other forms of the word, such as “reducing” or “reduction,” or “abrogating” or “abrogation” is meant lowering of an event or characteristic. It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to.

[0034] By “increase” or other forms of the word, such as “increasing,” is meant raising or elevating. It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to.

[0035] As used herein, by a “subject” is meant an individual. Thus, the “subject” can include domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, chickens, ducks, geese, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.), and birds. “Subject” can also include a mammal, such as a primate or a human. Thus, the subject can be a human or veterinary patient. The term “patient” refers to a subject under the treatment of a clinician, e.g., physician.

[0036] “Control” refers to a sample or standard used for comparison with an experimental sample. In some embodiments, the control is a sample obtained from a healthy subject (or a plurality of healthy subjects), such as a subject or subjects not expected or known to have a particular polymorphism. In additional embodiments, the control is a historical control or standard reference value or range of values (such as a previously tested control sample or plurality of such samples), or group of samples that represent baseline or normal values. In the specific context of the present invention, a “control” can be a non-engineered bacteria, or a bacteria that is not functionally competent, or a subject which is not treated with the bacteria. These are all exemplary and other uses of the term “control” can be imagined by one of skill in the art.

[0037] “Detecting” is used herein to identify the existence, presence, or fact of something. General methods of detecting are known to the skilled artisan and may be supplemented with the protocols and reagents disclosed herein. Detection can include a physical readout, such asAttorney Docket No. 10046-681W01

[0038] fluorescence output, or the results of treatment, such as detecting a reduction in a marker, disease, condition, or symptom.

[0039] The term "plasmid" as used herein refers to a construction comprised of genetic material designed to direct transformation of a targeted cell. The plasmid can comprise a plasmid backbone. A "plasmid backbone" as used herein contains multiple genetic elements positionally and sequentially oriented with other necessary genetic elements such that the nucleic acid in a nucleic acid cassette can be transcribed and when necessary, translated in the transfected cells. The term plasmid as used herein can refer to nucleic acid, e.g., DNA derived from a plasmid vector, cosmid, phagemid or bacteriophage, into which one or more fragments of nucleic acid may be inserted or cloned which encode for particular genes. This includes the construction comprised of extrachromosomal genetic material, usually of a circular duplex of DNA which can replicate independently of chromosomal DNA.

[0040] The term “non-chromosomal genetic element” refers to nucleic acid which is found within the bacterial cell but which is not incorporated into its chromosome. An example includes, but is not limited to, a plasmid. The plasmid can comprise genetic material for delivery into the target eukaryotic cell.

[0041] The term "genetic material" as used herein refers to contiguous fragments of DNA or RNA which is incorporated into the genetic element for delivery to a eukaryotic cell. The genetic material which is introduced into targeted cells can be any DNA or RNA. For example, the nucleic acid can be: (1) normally found in the targeted cells, (2) normally found in targeted cells but not expressed at physiologically appropriate levels in targeted cells, (3) normally found in targeted cells but not expressed at optimal levels in certain pathological conditions, (4) not normally found in the targeted cells, (5) novel fragments of genes normally expressed or not expressed in targeted cells, (6) synthetic modifications of genes expressed or not expressed within targeted cells, (7) any other DNA which may be modified for expression in targeted cells and (8) any combination of the above.

[0042] As used herein, an “internal ribosome entry site” or “IRES” refers to an element that promotes direct internal ribosome entry to the initiation codon, such as ATG, of a cistron (a protein encoding region), thereby leading to the cap-independent translation of the gene. See, e.g., Jackson et al., 1990. Trends Biochem Sci 15(12):477-83) and Jackson and Kaminski.

[0043] 1995. RNA 1(10):985-1000. In particular embodiments, the genetic elements (such as plasmids) contemplated by the invention, include one or more polynucleotides-of-interest that encode one or more polypeptides. To achieve efficient translation of each of the plurality ofAttorney Docket No. 10046-681W01

[0044] polypeptides, the polynucleotide sequences can be separated by one or more IRES sequences or polynucleotide sequences encoding self-cleaving polypeptides.

[0045] As used herein, the term “Kozak sequence” refers to a short nucleotide sequence that greatly facilitates the initial binding of mRNA to the small subunit of the ribosome and increases translation. The consensus Kozak sequence is (GCC)RCCATGG, where R is a purine (A or G) (Kozak, 1986. Cell. 44(2):283-92, and Kozak, 1987. Nucleic Acids Res.

[0046] 15(20):8125-48). In particular embodiments, the genetic elements, such as plasmids, contemplated by the invention, comprise polynucleotides that have a consensus Kozak sequence and that encode a desired polypeptide, e.g., ABCD1.

[0047] The term "flanking region" as used herein refers to nucleotide sequences on either side of an associated gene or nucleic acid sequence. Flanking regions can be either 5' or 3' to a particular gene or sequence in question. In general, flanking sequences contain necessary elements for replication, selection and maintenance of a plasmid, or expression of an inserted nucleic acid cassette or gene. Such elements include, but are not limited to, sequences such as replication origin, transcriptional terminator sequences, operator sequences, multicloning sites or restriction sites. These are meant to be examples only and nonlimiting.

[0048] The term "regulates," or "regulation" as used herein refers to sequences involved in control of a response or action. This includes sequences involved in regulating, controlling or affecting the expression of structural genes, or the replication, selection or maintenance of a plasmid. Examples include attenuators, operators and promoters. These are only examples and are meant to be nonlimiting.

[0049] The term "operon" is defined below. The term "promoter" as used herein refers to a region on a DN A molecule to which an RNA polymerase binds and initiates transcription. In an operon, the promoter is usually located at the operator end, adjacent but external to the operator. The nucleotide sequence of the promoter determines both the nature of the enzyme that attaches to it and the rate of RNA synthesis.

[0050] The term "copy number" as used herein refers to the number of plasmids in a cell that result from replication of a plasmid in a host. The copy number of plasmids per host cell can range from 1 to more than 1000.

[0051] The term "replication origin" as used herein refers to a nucleotide sequence at which DNA synthesis for the purpose of replicating the nucleic acid sequence begins. This is generally termed an ori site. Circular bacterial generally have a single ori site, whereas there are many ori sites on each eukaryotic chromosome. This term includes replicons, which as used herein refers to a genetic element that behaves as an autonomous unit during DNAAttorney Docket No. 10046-681W01

[0052] replication. In bacteria, the chromosome functions as a single replicon, whereas eukaryotic chromosomes contain hundreds of replicons in series.

[0053] The term "plasmid-containing cell" or "plasmid-bearing” as used herein refers to a cell transfected or transformed with a plasmid. Transfected and transformed are defined in more detail below.

[0054] The term “hybridization” is defined as forming base pairs between complementary regions of two strands of DNA, RNA, or between DNA and RNA, thereby forming a duplex molecule, for example. Hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the hybridization method and the composition and length of the hybridizing nucleic acid sequences. Generally, the temperature of hybridization and the ionic strength (such as the Na+ concentration) of the hybridization buffer will determine the stringency of hybridization. Calculations regarding hybridization conditions for attaining particular degrees of stringency are discussed in Sambrook et al., (1989) Molecular Cloning, second edition, Cold Spring Harbor Laboratory, Plainview, N. Y. (chapters 9 and 11).

[0055] An “isolated” biological component (such as a nucleic acid molecule) has been substantially separated, produced apart from, or purified away from other biological components. Nucleic acid molecules which have been “isolated” include nucleic acids molecules purified by standard purification methods, as well as those chemically synthesized. Isolated does not require absolute purity, and can include nucleic acid molecules that are at least 50% isolated, such as at least 75%’, 80%, 90%, 95%’, 98%, 99% or even 100% isolated.

[0056] A “nucleic acid” is a deoxyribonucleotide or ribonucleotide polymer, which can include analogues of natural nucleotides that hybridize to nucleic acid molecules in a manner similar to naturally occurring nucleotides. In a particular example, a nucleic acid molecule is a single stranded (ss) DNA or RNA molecule, such as a probe or primer. In another particular example, a nucleic acid molecule is a double stranded (ds) nucleic acid, such as a target nucleic acid. Examples of modified nucleic acids are those with altered backbones, such as peptide nucleic acids (PNA).

[0057] The major nucleotides of DNA are deoxyadenosine 5'-triphosphate (dATP or A), deoxyguanosine 5 '-triphosphate (dGTP or G), deoxycytidine 5 '-triphosphate (dCTP or C) and deoxythymidine '-triphosphate (dTTP or T). The major nucleotides of RNA are adenosine 5 '-triphosphate (ATP or A), guanosine 5 '-triphosphate (GTP or G), cytidine '-triphosphate (CTP or C) and uridine '-triphosphate (UTP or U).

[0058] Attorney Docket No. 10046-681W01

[0059] Nucleotides include those nucleotides containing modified bases, modified sugar moieties and modified phosphate backbones, as known in the art.

[0060] Examples of modified base moieties which can be used to modify nucleotides at any position on its structure include, but are not limited to: 5 -fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl -2-thiouridine, 5 -carboxy methyl aminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N-6-isopentenyladenine, 1-methylguanine, 1 -methylinosine, 2,2-dimethylguanine, 2- methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5 -methylaminomethyl uracil, methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5 '-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil- -oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5 -oxyacetic acid methylester, uracil-5-oxyacetic acid, 5-methyl-2-thiouracil, 3-(3-amino-3-N-2- carboxypropyl)uracil, and 2,6-diaminopurine.

[0061] Examples of modified sugar moieties which may be used to modify nucleotides at any position on its structure include, but are not limited to: arabinose, 2-fluoroarabinose, xylose, and hexose, or a modified component of the phosphate backbone, such as phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, or a formacetal or analog thereof.

[0062] The term “complementary binding” as used herein occurs when the base of one nucleic acid molecule forms a hydrogen bond to the base of another nucleic acid molecule. Normally, the base adenine (A) is complementary to thymidine (T) and uracil (U), while cytosine (C) is complementary to guanine (G ). For example, the sequence 5'-ATCG-3' of one ssDNA molecule can bond to 3'-TAGC-5' of another ssDNA to form a dsDNA. In this example, the sequence 5'-ATCG-3' is the reverse complement of 3'-TAGC-5'. Nucleic acid molecules can be complementary to each other even without complete hydrogen-bonding of all bases of each molecule. For example, hybridization with a complementary nucleic acid sequence can occur under conditions of differing stringency in which a complement will bind at some but not all nucleotide positions.

[0063] A “polymorphism” is a variation in a gene sequence. The polymorphisms can be those variations (DNA sequence differences, e.g., substitutions, deletions, or insertions) which are generally found between individuals or different ethnic groups and geographic locations which, while having a different sequence, produce functionally equivalent gene products.

[0064] Attorney Docket No. 10046-681W01

[0065] Typically, the term can also refer to variants in the sequence which can lead to gene products that are not functionally equivalent. Polymorphisms also encompass variations which can be classified as alleles and / or mutations which can produce gene products which may have an altered function. Polymorphisms also encompass variations which can be classified as alleles and / or mutations which either produce no gene product or an inactive gene product or an active gene product produced at an abnormal rate or in an inappropriate tissue or in response to an inappropriate stimulus. Alleles are the alternate forms that occur at the polymorphism.

[0066] Polymorphisms can be referred to, for instance, by the nucleotide position at which the variation exists, by the change in amino acid sequence caused by the nucleotide variation, or by a change in some other characteristic of the nucleic acid molecule or protein that is linked to the variation.

[0067] Methods for preparing and using nucleic acid probes are described, for example, in Sambrook et al. (In Molecular Cloning: A Laboratory Manual, CSHL, New York, 1989), Ausubel et al. (ed.) (In Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1998), and Innis et al. (PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc., San Diego, Calif., 1990).

[0068] The identity / similarity between two or more nucleic acid sequences is expressed in terms of the identity between the sequences. Sequence identity can be measured in terms of percentage identity; the higher the percentage, the more identical the sequences are.

[0069] Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith & Waterman, Adv. Appl. Math.

[0070] 2:482, 1981; Needleman & Wunsch, J. Mol. Biol. 48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988; Higgins & Sharp, Gene, 73:237-44, 1988; Higgins & Sharp, CABIOS 5:151-3, 1989; Corpet et al., Nuc. Acids Res. 16:10881-90, 1988; Huang et al. Computer Appls. in the Biosciences 8, 155-65, 1992; and Pearson et al., Meth. Mol. Bio.

[0071] 24:307-31, 1994. Altschul et al., J. Mol. Biol. 215:403-10, 1990, presents a detailed consideration of sequence alignment methods and homology calculations.

[0072] The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol.

[0073] 215:403-10, 1990) is available from several sources, including the National Center for Biotechnology (NCBI, National Library of Medicine, Building 38 A, Room 8N805, Bethesda, Md. 20894) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn, and tblastx. Additional information can be found at the NCBI web site. BLASTN is used to compare nucleic acid sequences. If the two compared sequences share homology, then the designated output file will present those regions of homology asAttorney Docket No. 10046-681W01

[0074] aligned sequences. If the two compared sequences do not share homology, then the designated output file will not present aligned sequences.

[0075] Once aligned, the number of matches is determined by counting the number of positions where an identical nucleotide or amino acid residue is presented in both sequences. The percent sequence identity is determined by dividing the number of matches either by the length of the sequence set forth in the identified sequence, or by an articulated length (such as 100 consecutive nucleotides or amino acid residues from a sequence set forth in an identified sequence), followed by multiplying the resulting value by 100. For example, a nucleic acid sequence that has 1166 matches when aligned with a test sequence having 1554 nucleotides is 75.0 percent identical to the test sequence (1166÷1554*100=75.0). The percent sequence identity value is rounded to the nearest tenth. For example, 75.11, 75.12, 75.13, and 75.14 are rounded down to 75.1, while 75.15, 75.16, 75.17, 75.18, and 75.19 are rounded up to 75.2. The length value will always be an integer. In another example, a target sequence containing a 20-nucleotide region that aligns with 20 consecutive nucleotides from an identified sequence as follows contains a region that shares 75 percent sequence identity to that identified sequence (that is, 15÷20*100=75). One indication that two nucleic acid molecules are closely related is that the two molecules hybridize to each other under stringent conditions, as described above.

[0076] A “sample,” such as a biological sample, is a sample obtained from a subject. As used herein, biological samples include all clinical samples useful for detection of a methylated nucleotide, including, but not limited to, cells, tissues, and bodily fluids, such as: blood; derivatives and fractions of blood, such as serum; urine; sputum; or CVS samples. In a particular example, a sample includes blood obtained from a human subject, such as whole blood or serum.

[0077] General Description

[0078] The present invention is the development of engineered bacteria, and methods of using the bacteria, to deliver RNA into mammalian cells for protein expression. These bacteria can gain entry to the cytoplasm of mammalian cells, but either do not cause disease naturally, or have been engineered not to cause disease. Instead, these bacteria release cargo into the mammalian cell cytoplasm. Disclosed herein are engineered bacteria which can express RNAs that are capable of circularization. Upon entry into the mammalian cell cytoplasm, the bacterial-produced circular RNA are released and can then be translated by the mammalian cells.

[0079] Attorney Docket No. 10046-681W01

[0080] Broadly, this system can be used to deliver RNA, such as mRNA, to a eukaryotic cell. This can be done in vitro or in vivo, such as a mode of therapy to a living organism. For example, the bacteria can be used for oral delivery of RNA to gut epithelial cells, or injected for delivery of RNA at distal sites (these are two of many examples which are further elucidated below). This system can be used in vaccine development (taking advantage of natural bacterial immune responses) but can also be used to deliver RNA relevant to diverse situations where gene therapy can be usefully applied, such as to treat autoimmune conditions, metabolic diseases, and cancer, etc. (More details of treatment strategies and specific diseases are provided below).

[0081] Bacteria

[0082] Based on this discovery, disclosed herein are engineered bacteria capable of invading a eukaryotic cell, wherein said bacteria comprises a non -chromosomal genetic element, wherein said genetic element comprises a template for expression of circular RNA (circRNA), such as circular mRNA, and further wherein the genetic element comprises one or more components which facilitate circRNA translation by a eukaryotic ribosome.

[0083] Disclosed herein are both bacteria that are capable of invading eukaryotic cells naturally, and those which have been engineered to do so. For example, Shigella, Salmonella, Listeria, Legionella, and Mycobacterium are all capable of eukaryotic cell invasion. Disclosed herein are engineered versions of these bacteria which have reduced virulence compared to a wild-type strain, or is growth-defective compared to a wild type strain, so that when used as a therapeutic, any infectious properties of the bacteria have been removed.

[0084] For example, modified and attenuated Salmonella typhimurium can be used for molecular delivery of antitumor drugs in cancer treatment, which can better control tumor growth and metastasis (Johnson 2021; Ahmed 2022). An example which has been used with the present method is strain VNP20009. Another example is Shigella CVD1208 (Kotloff 2024). Both Salmonella and Shigella naturally invade eukaryotic cells, but can be engineered to reduce or eliminate virulence or their ability to grow or carry out negative, or unwanted effects in the cell which it’s invaded.

[0085] Also contemplated are bacteria which are not naturally capable of invading a eukaryotic cell, but which have been engineered to do so. Examples include, but are not limited to, Escherichia coli K12 strains including W3110 and MG1655, and probiotic strains including Nissle. (Sansonetti 1983). These bacteria can comprise further modifications as well, such as reduced or eliminated virulence.

[0086] Attorney Docket No. 10046-681W01

[0087] As mentioned above, the bacterial cells disclosed herein can be modified, or engineered, in a number of ways. One of these ways includes the ability to lyse when released inside of a eukaryotic cell, or the ability to lyse at a faster rate. For example, lysis of the bacteria may increase by 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%,, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% compared to a non-engineered bacteria. Or, put another way, lysis may occur 2, 3, 4, 5, 6, 7, 8, or 10 times faster, or more.

[0088] The bacterial cells can also be engineered so that the contents of the bacteria are less damaged (more intact) when released in the eukaryotic cell than they would be if a nonengineered bacterial cell were to be lysed within the eukaryotic cell. This can be done by¬

[0089]

[0090] Attorney Docket No. 10046-681W01

[0091] 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% reduction compared to a non¬ engineered bacteria. The engineered bacteria can also be growth-defective compared to a wild type (non-engineered) strain. This reduction in growth can be a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%,

[0092] 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%,

[0093] 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%,

[0094] 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%,

[0095] 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% reduction compared to a non-engineered bacteria.

[0096] The engineered bacteria can also be engineered to comprise at least one other beneficial trait. One of skill in the art can readily envision what such beneficial traits could be. Examples include, but are not limited to, bacteria encoding enzymes that enhance intron splicing or other mechanisms of circRNA formation, bacteria with mutated nuclease and protease to enhance mRNA stability, and bacteria encoding elements to enhance target RNA transcription.

[0097] Non-Chromosomal Genetic Elements

[0098] The engineered bacteria disclosed herein carry a non-chromosomal genetic element within the bacterial cell, which is released upon entry into a eukaryotic cell. An example of a non-chromosomal genetic element includes, but is not limited to, a plasmid or bacterial artificial chromosome. Also contemplated are elements which are incorporated into the bacterial chromosome but which are not naturally occurring in that bacteria. 'This non-chromosomal genetic element, or the artificial chromosomal element, includes a “payload” which has a useful trait or characteristic, such as a therapeutic or diagnostic purpose. The nucleic acid found within the non-chromosomal genetic element can encode a gene, for example. That gene, when expressed, can provide a polypeptide, such as a protein, which has a therapeutic benefit to the organism to which it is delivered.

[0099] Suitable desirable genetic material for incorporation into the genetic element may be obtained from existing, including commercial, sources. One may also obtain new desirable genetic material encoding a protein of interest, for example, using any one or more of a variety of molecular biological techniques generally known to those skilled in the art. For example, cDNA or genomic libraries may be screened using primers or probes with designed

[0100] Attorney Docket No. 10046-681W01

[0101] sequences. Polymerase chain reaction (PCR™) may also be used to generate genetic material encoding a desired protein of interest.

[0102] After identifying appropriate desired genetic material, it may be inserted into any one of the many genetic elements currently known in the art (such as a plasmid), so that it will direct the expression and production of the selected protein when released into a target eukaryotic cell. For example, the coding portion of the DNA segment can be positioned under the control of a promoter / enhancer element. The promoter may be in the form of the promoter that is naturally associated with a selected gene, as may be obtained by isolating the 5' non¬ coding sequences located upstream of the coding segment or exon, for example, using recombinant cloning and / or PCR technology. The promoter maybe inducible to allowed for controlled expression of the mRNA to be circularized. The plasmid may contain transcription terminators and elements to promote stabilization.

[0103] As described above, the genetic element, such as the plasmid, can comprise components which facilitate circRNA translation by a eukaryotic ribosome. These can comprise, but are not limited to, a Kozak sequence, an IRES, aptamer, and / or machinery for capping mRNA.

[0104] Further, the non-chromosomal genetic element encodes can encode a split intron that facilitates formation of circRNA upon transcription. The intron may be a group I including the T4 td intron. Further, the non-chromosomal genetic element could encode the circRNA by driving linear RNA product ligated into circular' form by a protein ligase expressed in the bacteria. See, for example, Perriman 1998 and Obi 2021, both incorporated by reference in their entirety for their teaching concerning introns.

[0105] Eukaryotic Cells and Treatment Methods

[0106] As described above, the engineered bacterial cell comprising a non-chromosomal genetic element can invade a eukaryotic cell. This eukaryotic cell can be, for example, a mammalian cell, such as from a domesticated animal (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, chickens, ducks, geese, sheep, goats, etc.), a laboratory animal (e.g., mouse, rabbit, rat, guinea pig, etc.), or a bird. Also envisioned are in vivo uses, where the subject which is treated is a mammal, such as a primate or a human. Disclosed herein is a eukaryotic cell comprising the engineered bacteria, including the genetic element, described herein.

[0107] Described herein is a composition for treatment of a subject comprising the bacterial cell described herein, or a eukaryotic cell which the bacterial cell has invaded (referred toAttorney Docket No. 10046-681W01

[0108] herein as “invaded” or “penetrated” eukaryotic cell ). The eukaryotic cell can export a protein encoded by the circRNA, for example. The engineered eukaryotic cell can have a variety of characteristics, such as a metabolism which differs from the wild type cell, an altered signal transduction pathway, a modified genome, and / or a modified epigenome. This composition can further comprise an adjuvant, carrier, or diluent. The composition can be formulated for oral, intravenous, or parenteral administration. In one example, the composition can be a vaccine.

[0109] Also disclosed is a method of delivering a therapeutic composition to a subject in need thereof, the method comprising administering to the subject an engineered bacteria capable of invading a eukaryotic cell, wherein said bacteria comprises a non-chromosomal genetic element, wherein said genetic element comprises a template for expression of circRNA, and further wherein the genetic element comprises one or more components which facilitate circRNA translation by a eukaryotic ribosome.

[0110] Upon delivery of the engineered bacteria to the subject: a) the engineered bacteria enters one or more cells of the subject, b) contents of the bacteria are released into the one or more cells, c) the circRNA of the bacteria is expressed and subsequently translated, and d) one or more resulting translation produces) provide therapeutic benefit to the subject. The translation product can comprise a therapeutic peptide, an antibody, a hormone, an enzyme, an enzyme inhibitor, an antigen, an adjuvant, a chemokine, or a cytokine. Additional therapeutic agents can also be provided to the subject as needed.

[0111] By “amount that is sufficient to treat the subject” or “effective amount” which are used herein interchangeably is meant to be an amount of a bacterium or bacteria, high enough to significantly positively modify the condition to be treated but low enough to avoid serious side effects (at a reasonable benefit / risk ratio), within the scope of sound medical judgment. An effective amount of a bacterium will vary with the particular goal to be achieved, the age and physical condition of the subject being treated, the duration of treatment, the nature of concurrent therapy and the specific bacterium employed. The effective amount of a bacterium will thus be the minimum amount, which will provide the desired effect. Usually an amount from about 103to about 109bacteria e.g. from about 105to about 109bacteria / m2body surface.

[0112] Examples of substances which can serve as pharmaceutical carriers are sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethycellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; calcium carbonate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil,Attorney Docket No. 10046-681W01

[0113] corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, manitol, and polyethylene glycol; agar; alginic acids; pyrogen-free water; isotonic saline; cranberry extracts and phosphate buffer solution; skim milk powder; as well as other non-toxic compatible substances used in pharmaceutical formulations such as Vitamin C, estrogen and echinacea, for example. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, lubricants, excipients, tabletting agents, stabilizers, antioxidants and preservatives, can also be present.

[0114] Modes of administration of the engineered bacteria to a subject may be selected from the group consisting of intravenous, intratumoral, intraperitoneal and per-oral administration. Although this invention is not intended to be limited to any particular mode of application, intravenous or intratumoral administration of the bacteria or the pharmaceutical compositions is preferred.

[0115] Depending on the route of administration, the active ingredients which comprise bacteria may be required to be coated in a material to protect said organisms from the action of enzymes, acids and other natural conditions which may inactivate said organisms. In order to administer bacteria by other than parenteral administration, they should be coated by, or administered with, a material to prevent inactivation. For example, bacteria may be coadministered with enzyme inhibitors or in liposomes. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DFP) and trasylol. Liposomes include water- in-oil-in-water P40 emulsions as well as conventional and specifically designed liposomes which transport bacteria, such as Lactobacillus, or their by-products to an internal target of a host subject. One bacterium may be administered alone or in conjunction with a second, different bacterium. Any number of different bacteria may be used in conjunction. By “in conjunction with” is meant together, substantially simultaneously or sequentially. The compositions may be also administered in the form of tablet, pill or capsule, for example, such as a freeze-dried capsule comprising the bacteria or the pharmaceutical compositions of the present invention or as frozen solution of bacteria or the pharmaceutical compositions of the present invention containing DMSO or glycerol. Another preferred form of application involves the preparation of a lyophilized capsule of the bacteria or the pharmaceutical compositions of the present invention. Still another preferred form of application involves the preparation of a heat dried capsule of the bacteria or the pharmaceutical compositions of the present invention.

[0116] The engineered bacteria or the pharmaceutical composition to be administered can be administered by injection. Forms suitable for injectable use include aseptic or sterileAttorney Docket No. 10046-681W01

[0117] aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases the form must be aseptic or sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0118] The invention will now be described further with reference to the following examples, which are presented for illustrative purposes only and are not to be construed as limiting the scope of the invention as defined by the appended claims.

[0119] EXAMPLES

[0120] Example 1 - Shigella Lung Model Luciferase Assay

[0121] Purpose: To dose Nano Luciferase circRNA transcripts in Shigella to mice and get production of Luciferase protein after 72 hours.

[0122] Stocks:

[0123] NanoLuc LVA in CVD1208 (Carb)

[0124] NanoLuc LVA No Intron in CVD1208 (Carb)

[0125] Day 0:

[0126] 1. Make ONC of the stocks listed above in TSB + Guanine + Carb.

[0127] Day 1:

[0128] 1. Back dilute cultures to an OD600 of 0.1 in 5niL TSB + Guanine + Carb.

[0129] 2. Grow cultures to log phase (OD ~0.4), then add ImM IPTG. Return to 37C shaker for 4 hours.

[0130] 3. Normalized cultures to an OD of 1.0 in ImL of PBS.

[0131] 4. Wash once with PBS, resuspend in ImL PBS.

[0132] 5. Anesthetize mice and nasally administer samples into each mouse.

[0133] 6. Place treated mice in new cage and non-treated mice in another.

[0134] Day 2-3:

[0135] Attorney Docket No. 10046-681W01

[0136] 1. Check mice every day.

[0137] Day 3:

[0138] 1. Harvest lungs from each mouse and grind each in 5mL of PBS.

[0139] 2. Once homogenous, spin down for 5 minutes at 4000g in the centrifuge.

[0140] 3. Pull off lOOuL of supernatant and add to a black bottom 96-well plate. Plate in triplicate.

[0141] 4. Constitute NL substrate solution at a ratio of 1:20 NL substrate to NL substrate buffer. The volume necessary per well to assay is 25 uL.

[0142] 5. Pipette 25 uL of NL substrate solution into each well to assay your 96-well plate and pipette up and down twice to mix.

[0143] 6. Insert plate into plate reader and run "‘split luciferase AO copy” protocol.

[0144] 7. While plate is running, plate lOOuL of each lung supernatant onto TSA + Guanine + Carb and spread with beads. Check next day for any residual bacterial growth.

[0145] Example 2 - HeLa Cell Invasion and NanoLuc Expression Assay

[0146] Purpose: Assess expression of nanoluc (NL) LVA on different promoter backbone combinations in HeLa cells. Cells and bacteria will be plated on Day 1, cells will be infected with bacteria on Day 2, and NL will be measured on Days 3-5.

[0147] Stocks:

[0148] - pMMB NL LVA (in CVD1208)

[0149] - pBAD cat NL LVA (in CVD1208)

[0150] - pMMB N LVA No Intron (in C VD 1208)

[0151] Day 1: Plate HeLa cells + bacteria

[0152] 1. Make ONCs of the appropriate bacteria for infection onto selection plates & let grow ON

[0153] 2. Plate HeLa cells in a 12-well plate at a concentration of 0.2xl0A6 cells / well in 1 mL for 100% confluency the following day

[0154] Day 2: Infect cells

[0155] 1. Dilute ONCs to an OD of 0.5. Add IPTG to inducible constructs. Place all cultures back in shaking incubator for 4 hours.

[0156] 2. Normalize ODs to 0.5 in lOmL. Pellet cells by centrifuging at 5000 rpm for 5 mins & remove LB.

[0157] Attorney Docket No. 10046-681W01

[0158] Resuspend in lOmL DMEM + ImM IPTG + 10% FBS.

[0159] Get HeLa cells (12-well plates from TC room), aspirate media, and wash cells w / 1 mL PBS.

[0160] Aspirate PBS and add 1 mL infective media to each well diluted at MOI 1000. Incubate @ 37C in incubator for 2 hours.

[0161] Aspirate infective media and wash HeLa cells 3x w / 1 mL PBS.

[0162] Aspirate PBS and replace w / 1 mL DMEM + 1 mM IPTG + 10% FBS + 1% Gentamicin.

[0163] Incubate @ 37C in incubator overnight.

[0164] Day 3-5: Collection

[0165] Aspirate media and wash HeLa cells 3x w / 1 mL PBS.

[0166] Add 500 uL TE / well and rock on shaker until cells are detached (3-5 mins).

[0167] Add 5()0uL of DMEM + 10%’ FBS. Pipette up and down to homogenize contents of well. Transfer contents of each well into a labeled microfuge tube. Centrifuge at 800xg / G for 5 minutes to pellet cells.

[0168] Aspirate TE and resuspend cell pellets in 100 uL of PBS + 0.1% BSA (10 mL PBS + 10 mg BSA).

[0169] Flash freeze samples and store in the -80C.

[0170] Luciferase Assay

[0171] Transfer all lOOuL of samples from each timepoint to a corresponding well in a 96- well black sided plate.

[0172] Constitute NL substrate solution at a ratio of 1:20 NL substrate to NL substrate buffer. The volume necessary per well to assay is 25 uL.

[0173] Pipette 25 uL of NL substrate solution into each well to assay your 96- well plate and pipette up and down twice to mix.

[0174] Insert plate into plate reader and ran “split luciferase AO copy” protocol.

[0175]

[0176] Attorney Docket No. 10046-681W01

[0177] REFERENCES

[0178] Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, Chakraborty T, Weiss S. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell. 1997 Dec 12;91(6):765-75.

[0179] Chen R, Wang SK, Belk JA, Amaya L, Li Z, Cardenas A, Abe BT, Chen CK, Wender PA, Chang HY. Engineering circular RNA for enhanced protein production. Nat Biotechnol. 2023 Feb;41(2):262-272.

[0180] Huang, A. et al. (2020). " Engineered circular RNAs protect the heart from ischemia / reperfusion injury." Molecular Therapy, 28(7), 1795-1805.

[0181] Li, Z. et al. (2015). " Exon-intron circular RNAs regulate transcription in the nucleus." Nature Structural & Molecular Biology, 22(3), 256-264.

[0182] Liu, C. X. et al. (2022). " Design and delivery of therapeutic circular RNAs for cancer treatment." Nature Reviews Drug Discovery, 21(7), 477-495.

[0183] Yang, Y. et al. (2017). " Extensive translation of circular RNAs driven by N6- methyladenosine." Cell Research, 27(5), 626-641.

[0184] Zhang, M. et al. (2021). " Synthetic circRNA functions as a miR-21 sponge to suppress glioblastoma tumorigenesis." Molecular Therapy - Nucleic Acids, 23, 339-351.

[0185] Zhou, W. Y. et al. (2022). " Circular RNA therapeutics: current strategies and future perspectives." Cell & Bioscience, 12(1), 83.

[0186] Zhang, Y., Tang, Z., Shao, Y. et al. Attenuated Salmonella typhimurium L forms suppress tumor growth and promote apoptosis in murine ovarian tumors. Sci Rep 14, 16045 (2024).

[0187] Obi P, Chen YG. The design and synthesis of circular RNAs. Methods. 2021 Dec;196:85-103. doi: 10.1016 / j.ymeth.2021.02.020. Epub 2021 Mar 2.

[0188] Troxell B, Mendoza M, Ali R, Koci M, Hassan H. Attenuated Salmonella enterica Serovar Typhimurium, Strain NC983, Is Immunogenic, and Protective against Virulent Typhimurium Challenges in Mice. Vaccines (Basel). 2020 Nov 3;8(4):646.

[0189] Johnson, S. A. et al. Monocytes mediate Salmonella typhimurium-induced tumor growth inhibition in a mouse melanoma model. 2021. Eur. J. Immunol. 51(12), 3228-3238.

[0190] Ahmed, S. G. et al. Intratumoral injection of schwannoma with attenuated Salmonella typhimurium induces antitumor immunity and controls tumor growth. Proc. Natl. Acad. Sci. USA 119(24), e2202719119. https: / / doi.org / 10.1073 / pnas.2202719119 (2022).

[0191] Attorney Docket No. 10046-681W01

[0192] Karen L. Kotloff, Marcela F. Pasetti, Eileen M. Barry, James P. Nataro, Steven S.

[0193] Wasserman, Marcelo B. Sztein, William D. Picking, Myron M. Levine, Deletion in the Shigella Enterotoxin Genes Further Attenuates Shigella flexneri 2a Bearing Guanine Auxotrophy in a Phase 1 Trial of CVD 1204 and CVD 1208, The Journal of Infectious Diseases, Volume 190, Issue 10, 15 November 2004, Pages 1745-1754.

[0194] Sansonetti PJ, Hale TL, Dammin GJ, Kapfer C, Collins HH Jr, Formal SB.

[0195] Alterations in the pathogenicity of Escherichia coli K-12 after transfer of plasmid and chromosomal genes from Shigella flexneri. Infect Immun. 1983 Mar;39(3): 1392-402.

[0196] Perriman R, Ares M Jr. Circular mRNA can direct translation of extremely long repeating-sequence proteins in vivo. RNA. 1998 Sep;4(9): 1047-54.

[0197] Obi P, Chen YG. The design and synthesis of circular RNAs. Methods. 2021

[0198] Dec;196:85-103. doi: 10.1016 / j.ymeth.2021.02.020

Claims

Attorney Docket No. 10046-681 WO 1WHAT IS CLAIMED IS:

1. An engineered bacteria capable of invading a eukaryotic cell, wherein said bacteria comprises a non-chromosomal genetic element, wherein said genetic element comprises a template for expression of circular mRNA (circRNA), and further wherein the genetic element comprises one or more components which facilitate circRNA translation by a eukaryotic ribosome.

2. The engineered bacteria of claim 1, wherein the components that facilitate circRNA translation by a eukaryotic ribosome comprise a Kozak sequence, an IRES, and / or machinery for capping mRNA.

3. The engineered bacteria of claim 1 or 2, wherein the bacteria naturally invades eukaryotic cells, and comprises Shigella, Salmonella, Listeria, Legionella, or Mycobacterium, or wherein the bacteria does not naturally invade cells, but has been engineered to do so.

4. The engineered bacteria of any one of claims 1-3, wherein the bacteria has been attenuated to reduce virulence compared to a wild-type strain, or is growth-defective compared to a wild type strain.

5. The engineered bacteria of any one of claims 1-4, wherein the bacteria has been engineered to lyse when inside a eukaryotic cell.

6. The engineered bacteria of any one of claims 1-5, wherein the non-chromosomal genetic element comprises a plasmid.

7. The engineered bacteria of any one of claims 1-6, wherein the non-chromosomal genetic element encodes a split intron that facilitate formation of circRNA upon transcription.

8. The engineered bacteria of any one of claims 1-7, wherein the eukaryotic cell is a mammalian cell.Attorney Docket No. 10046-681 WO 19. The engineered bacteria of any one of claims 3-8, wherein the bacteria has been engineered to regulate transcription, circularization, or translation, and / or to comprise at least one additional beneficial mutation.

10. A eukaryotic cell comprising the engineered bacteria of any one of claims 1-9, wherein the eukaryotic cell exports a protein encoded by the circRNA.

11. A composition for treatment of a subject comprising the eukaryotic cell of any one of claims 1-9.

12. The composition of claim 11, wherein said composition further comprises an adjuvant, carrier, or diluent.

13. The composition of claim 11 or 12, wherein the composition is formulated for oral, intravenous, or parenteral administration.

14. The composition of any one of claims 11-13, wherein the composition is a vaccine.

15. A method of delivering a therapeutic composition to a subject in need thereof, the method comprising administering to the subject an engineered bacteria capable of invading a eukaryotic cell, wherein said bacteria comprises a non-chromosomal genetic element, wherein said genetic element comprises a template for expression of circRNA, and further wherein the genetic element comprises one or more components which facilitate circRNA translation by a eukaryotic ribosome.

16. The method of claim 15, wherein, upon delivery of the engineered bacteria to the subject: a) the engineered bacteria enters one or more cells of the subject, b) contents of the bacteria are released into the one or more cells, c) the circRNA of the bacteria is expressed and subsequently translated, and d) one or more resulting translation product(s) provide therapeutic benefit to the subject.

17. The method of claim 16, wherein the translation product comprises an antibody, a hormone, an enzyme, an antigen, an adjuvant, or a cytokine.

18. The method of any one of claims 15-17, wherein the subject is a mammal.Attorney Docket No. 10046-681 WO 119. The method of claim 18, wherein the subject is a human.

20. The method of any one of claims 15-19, wherein an additional therapeutic agent is given to the subject.